abstract |
In one aspect, the invention relates to highly galactosylated anti-HER2 antibodies and compositions thereof. In one aspect, the invention relates to a population of anti-HER2 antibodies having a high degree of galactosylation, and compositions thereof. In one aspect, the invention relates to methods of making and using a highly galactosylated anti-HER2 antibody with a population of highly galactosylated anti-HER2 antibodies. In certain embodiments, the anti-HER-2 antibody is trastuzumab. |